Matthew J. Maenner

Matthew J. Maenner

Auto-generated profile, based on publicly available information

Matthew J. Maenner

National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 4770 Buford Highway NE, (MS S106-4), Atlanta, GA, 30341, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2023 in Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
MMMatthew J. Maenner
Matthew J. Maenner
This report describes CDC findings from the Autism and Developmental Disabilities Monitoring Network for children aged 8 years in 2020.

10 May 2020 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
PDPatricia M. Dietz
Patricia M. Dietz
CRCharles Rose
Charles Rose
DMDedria McArthur
Dedria McArthur
MMMatthew Maenner
Matthew Maenner

1 March 2016 in Annals of Epidemiology
Verified
Journal Article
Closed access
MMMatthew J. Maenner
Matthew J. Maenner
SBStephen J. Blumberg
Stephen J. Blumberg
MKMichael D. Kogan
Michael D. Kogan
DCDeborah Christensen
Deborah Christensen
MYMarshalyn Yeargin-Allsopp
Marshalyn Yeargin-Allsopp
LSLaura A. Schieve
Laura A. Schieve

21 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMatthew J Maenner
Matthew J Maenner
MYMarshalyn Yeargin-Allsopp
Marshalyn Yeargin-Allsopp
KBKim Van Naarden Braun
Kim Van Naarden Braun
DCDeborah L Christensen
Deborah L Christensen
LSLaura A Schieve
Laura A Schieve
The Autism and Developmental Disabilities Monitoring (ADDM) Network conducts population-based surveillance of autism spectrum disorder (ASD) among 8-year old children in multiple US sites. To classify ASD, trained clinicians review developmental evaluations collected from multiple health and education sources to determine whether the child meets the ASD surveillance case criteria. The number of evaluations collected has dramatically increased since the year 2000, challenging the resources and timeliness of the surveillance system. We developed and evaluated a machine learning approach to classify case status in ADDM using words and phrases contained in children’s developmental evaluations. We trained a random forest classifier using data from the 2008 Georgia ADDM site which included 1,162 children with 5,396 evaluations (601 children met ADDM ASD criteria using standard ADDM methods). The classifier used the words and phrases from the evaluations to predict ASD case status. We evaluated its performance on the 2010 Georgia ADDM surveillance data (1,450 children with 9,811 evaluations; 754 children met ADDM ASD criteria). We also estimated ASD prevalence using predictions from the classification algorithm. Overall, the machine learning approach predicted ASD case statuses that were 86.5% concordant with the clinician-determined case statuses (84.0% sensitivity, 89.4% predictive value positive). The area under the resulting receiver-operating characteristic curve was 0.932. Algorithm-derived ASD “prevalence” was 1.46% compared to the published (clinician-determined) estimate of 1.55%. Using only the text contained in developmental evaluations, a machine learning algorithm was able to discriminate between children that do and do not meet ASD surveillance criteria at one surveillance site.

1 February 2016 in Emerging Infectious Diseases
Verified
Journal Article
Open access
SCSamuel J. Crowe
Samuel J. Crowe
MMMatthew J. Maenner
Matthew J. Maenner
SKSolomon Kuah
Solomon Kuah
BEBobbie Rae Erickson
Bobbie Rae Erickson
MCMegan Coffee
Megan Coffee
JTJonathan S. Towner
Jonathan S. Towner
To determine whether 2 readily available indicators predicted survival among patients with Ebola virus disease in Sierra Leone, we evaluated information for 216 of the 227 patients in Bo District during a 4-month period. The indicators were time from symptom onset to healthcare facility admission and quantitative real-time reverse transcription PCR cycle threshold (Ct), a surrogate for viral load, in first Ebola virus–positive blood sample tested. Of these patients, 151 were alive when detected and had reported healthcare facility admission dates and Ct values available. Time from symptom onset to healthcare facility admission was not associated with survival, but viral load in the first Ebola virus–positive blood sample was inversely associated with survival: 52 (87%) of 60 patients with a Ct of >24 survived and 20 (22%) of 91 with a Ct of <24 survived. Ct values may be useful for clinicians making treatment decisions or managing patient or family expectations.